GlassScriptPhysician profile
Benjamin Nia
NPI 1003312729
$3,813.35
in general payments reported to CMS, 2019-2025
21 companies · $508 in 2025
The $508 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $386 · 2021: $641 · 2022: $846 · 2023: $468 · 2024: $965 · 2025: $508.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,941.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,940.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $918.16 | 2021-2025 | |
| Leo Pharma INC. | $517.04 | 2023-2025 | Adbry, Anzupgo |
| Regeneron Healthcare Solutions, INC. | $422.95 | 2021-2023 | Libtayo, Dupixent |
| Novartis Pharmaceuticals Corporation | $349.92 | 2022-2025 | |
| Pfizer INC. | $321.57 | 2019-2023 | |
| E.R. Squibb & Sons, L.L.C. | $263.76 | 2022-2024 | Sotyktu |
| Dermavant Sciences, INC. | $133.11 | 2022-2024 | Vtama |
| Helsinn Therapeutics (U.S.), INC. | $125.00 | 2019 | |
| Amgen INC. | $115.54 | 2024-2025 | Otezla, Otezla |
| Genzyme Corporation | $105.07 | 2023-2024 | |
| Ucb, INC. | $103.06 | 2022-2025 | Bimzelx |
| Vyne Pharmaceuticals INC. | $84.37 | 2021 | |
| Almirall LLC | $83.06 | 2023-2025 | Seysara, Klisyri |
| Lilly USA, LLC | $76.31 | 2024-2025 | Taltz, Ebglyss, Olumiant |
| Incyte Corporation | $52.99 | 2023-2024 | Opzelura |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $37.54 | 2023-2024 | Absorica Ld, Winlevi |
| Strata Skin Sciences, INC. | $27.70 | 2025 | Xtrac |
| Medimetriks Pharmaceuticals, INC. | $21.71 | 2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $21.49 | 2024 | Jublia, Cabtreo, Arazlo |
| Janssen Biotech, INC. | $17.69 | 2022 | |
| Galderma Laboratories, L.P. | $15.31 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Nia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.